ATLASRein Therapeutics (RNTX) earnings date: Nov 13, 2026
Rein Therapeutics (RNTX) reports earnings for the quarter ended Sep 30, 2026 on Fri, Nov 13, 2026. Analysts expect EPS of -$0.10.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on RNTX
| Last price | $0.67 (-7.8%) |
|---|---|
| Normal 1-day range (±1σ) | ±6.9% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Rein Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Rein Therapeutics reports on Nov 13, 2026. One email the day before, with ATLAS’s read on Rein Therapeutics. You can switch it off at any time.
Alert me before RNTX reportsFree to start. Creating an account takes under a minute.
Notify me when Rein Therapeutics reports
Track RNTX free Add Rein Therapeutics to a free ATLAS watchlist and see its next report date in one place.
RNTX earnings at a glance
| Next report (confirmed) | Fri, Nov 13, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.10 |
| Last report | Aug 14, 2026 · Beat |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | -71.3% |
| Average move around a report | ±4.9% (last 4) |
| Sector | Healthcare · Biotechnology |
Rein Therapeutics earnings history: last 4 reports
Rein Therapeutics last reported on Aug 14, 2026: EPS of -$0.10 against an estimate of -$0.17 (+41.2% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 14, 2026 | -$0.17 | -$0.10 | +41.2% | Beat | +6.7% |
| May 15, 2026 | -$0.49 | -$0.19 | +61.2% | Beat | -8.0% |
| Mar 26, 2026 | -$0.21 | -$1.22 | -481.0% | Miss | -3.9% |
| Feb 6, 2026 | $3.18 | $6.15 | +93.4% | Beat | +0.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for RNTX
See the fair value, the probability range and the earnings history of Rein Therapeutics on its ATLAS page.
Rein Therapeutics (RNTX) stock analysisPlans from €3.99 a month.
Rein Therapeutics earnings: frequently asked questions
When does Rein Therapeutics (RNTX) report earnings?
Rein Therapeutics is scheduled to report on Friday, November 13, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for RNTX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.10 per share (USD). Estimates can change before the report.
How often does RNTX beat earnings estimates?
Of its last 4 reports with a recorded result, Rein Therapeutics beat the EPS estimate 3 times; the average surprise was -71.3%. Past results do not predict the next one.
How much does RNTX move around earnings?
Over its last 4 reports the stock moved an average of 4.9% (absolute, from the close before the report day to the close after it), and finished higher 2 of 4 times.
Did Rein Therapeutics beat earnings estimates last quarter?
Rein Therapeutics last reported on Aug 14, 2026: EPS of -$0.10 against an estimate of -$0.17 (+41.2% surprise), a beat.
How much does RNTX usually move in a day?
On a normal trading day the ATLAS model puts RNTX’s one-day range at about ±6.9%, with a 48% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Fri, Nov 13, 2026
Educational information, not investment advice. Disclaimer